Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 2/2014

01-02-2014 | Capsule Commentary

Capsule Commentary on Turner et al., Chronic Opioid Therapy Risk Reduction Initiative: Impact on Urine Drug Testing Rates and Results

Author: Ben A. Rich, JD, PhD

Published in: Journal of General Internal Medicine | Issue 2/2014

Login to get access

Excerpt

This study assessed the impact of a multi-faceted risk reduction initiative for patients on opioid therapy.1 It focused on urine drug screening (UDS), and noted that although the initiative increased UDS (from 7 to 50 %), that rate was well below the initiative’s target. Moreover, there was no commensurate impact on the rate of abnormalities identified, such as marijuana or illicit drugs. …
Literature
1.
Turner JA, Saunders K, Shortreed SM, Rapp SE, Thielke S, LeResche L, Riddell KM, Von Korff M. Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results. J Gen Intern Med. 2013; doi: 10.​1007/​s11606-013-2651-6.PubMed
2.
Gourlay D, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6:107–12.PubMedCrossRef
3.
Arnold RM, Han PJK. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am J Med. 2006;119:292–6.PubMedCrossRef
4.
5.
Metadata
Title
Capsule Commentary on Turner et al., Chronic Opioid Therapy Risk Reduction Initiative: Impact on Urine Drug Testing Rates and Results
Author
Ben A. Rich, JD, PhD
Publication date
01-02-2014
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 2/2014
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2675-y

Other articles of this Issue 2/2014

Journal of General Internal Medicine 2/2014 Go to the issue

Healing Arts

Diwali in the HIV Ward

Editorial Comment

Optimizing the Involvement of Language Interpreters During the Clinical Encounter

Original Research

Directive Counsel and Morally Controversial Medical Decision-Making: Findings from Two National Surveys of Primary Care Physicians

Editorial

Only Connect

Capsule Commentary

Capsule Commentary on Radin, Pitfalls in Hemoglobin A1c Measurement: When Results May Be Misleading

Capsule Commentary

Capsule Commentary on Patrick et al., Trends in Insulin Initiation and Treatment Intensification among Patients with Type 2 Diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits